ANVISA launched an investigation into rare vision loss cases linked to weight loss pens. Here is what patients and healthcare providers need to know about NAION and GLP-1 medications.
Regulatory agencies worldwide are examining a potential connection between popular weight loss medications and a rare but serious eye condition. ANVISA, Brazil's health regulatory agency, opened an investigation into cases of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) reported in patients using canetas emagrecedoras, injectable treatments that have grown massively in popularity. The FDA updated labeling for semaglutide products to include information about NAION risk, and Health Canada has published safety communications on this topic. Understanding what is known and what remains uncertain can help patients and healthcare providers make more informed decisions.
ANVISA's Investigation: What Triggered the Alert on Weight Loss Pens and Vision Loss?
In early 2025, ANVISA formally initiated an investigation after receiving reports of NAION in patients using GLP-1 based weight loss medications. The agency acted following international alerts that had already been circulating for months. The FDA first added labeling information about NAION risk to semaglutide products in 2024, acknowledging reports of vision loss in users. Health Canada similarly stated it was reviewing the evidence. ANVISA's move brought the discussion closer to Brazilian patients and healthcare providers, raising important questions about screening and monitoring during treatment with these medications.
Understanding NAION: Why This Eye Condition Is Different From Typical Side Effects
NAION stands for Non-Arteritic Anterior Ischemic Optic Neuropathy. It occurs when blood flow to the front portion of the optic nerve is suddenly reduced, causing optic nerve damage. The optic nerve carries visual information from the retina to the brain, and when its blood supply is compromised, vision loss follows. What makes NAION particularly concerning is its potential irreversibility. Unlike some medication side effects that resolve when the drug is stopped, NAION-related vision loss often does not recover fully.
Several factors increase a person's baseline risk for NAION. These include having a structurally small or crowded optic nerve disc, a condition sometimes called "disc at risk," as well as conditions that affect blood vessels such as hypertension, diabetes, and sleep apnea. The annual incidence of NAION in the general population is estimated between 2 and 10 per 100,000 people, making it uncommon but not extraordinarily rare. Cases can affect one eye or, in a smaller proportion of patients, both eyes over time.
Which Medications Are Under Scrutiny and How They Might Affect Vision
Both semaglutide and tirzepatida are under investigation. These medications work as GLP-1 receptor agonists, mimicking a hormone that regulates appetite and blood sugar. Tirzepatida, sold as Mounjaro and Zepbound, goes a step further as a dual GIP/GLP-1 agonist, which gives it a somewhat different mechanism of action compared to semaglutide. Both drugs have demonstrated significant weight loss results in clinical trials. The SURMOUNT-1 study, published in the New England Journal of Medicine, showed substantial body weight reduction in participants using tirzepatida over 72 weeks.
Researchers have proposed two main hypotheses for how these medications might be linked to NAION. The first centers on the rapid weight loss these drugs produce. When patients lose weight quickly, blood pressure can fluctuate, and some experts believe this may affect the delicate blood flow to the optic nerve. The second hypothesis suggests a more direct effect, where the medications may influence blood vessels in the eye independent of weight loss. The dual agonism of tirzepatida raises the question of whether its mechanism might carry a different risk profile, though no conclusive evidence exists on this point yet.
What the Data Actually Shows and What It Does Not
The evidence reviewed by regulatory agencies is largely observational and based on adverse event reports. The FDA's FAERS database has captured reports linking both semaglutide and tirzepatida to NAION, but these reports do not establish causation. Observational studies and case reports published in peer-reviewed journals have described NAION occurring in patients using these medications, but the total number of cases remains small relative to the millions of people using these drugs worldwide.
One critical point is that NAION occurs spontaneously in the general population at a known baseline rate. Determining whether patients using GLP-1 medications have a genuinely elevated risk requires controlling for the underlying conditions that predispose people to both obesity and NAION, such as diabetes and hypertension. Without large controlled studies, it is difficult to say with certainty whether the observed cases represent a true drug effect or coincidental occurrence. Regulatory agencies emphasize that the benefits of these medications for approved indications continue to be recognized, and patients should not stop treatment without consulting their healthcare providers.
If you are following updates on tirzepatida and want a single resource that tracks regulatory changes and emerging evidence, bookmark TirzeBlog for ongoing coverage as this situation develops.
Practical Guidance for Patients and Clinicians Amid the Investigation
For patients considering or currently using weight loss pens, several practical steps can help manage risk. Before starting treatment, patients with known risk factors for NAION, such as a crowded optic disc, hypertension, or diabetes, should discuss this potential concern with their prescribing physician. An ophthalmologic baseline evaluation may be advisable for those with elevated baseline risk, though routine eye screening for all patients is not yet standard practice.
During treatment, patients should be aware of warning signs that require urgent evaluation. Sudden vision loss, a curtain or shadow over part of the visual field, new blind spots, or color vision changes all warrant immediate medical attention. It is important to note that spontaneous visual recovery can occur in a minority of NAION cases, but early diagnosis is still important for managing the condition and monitoring the second eye.
Decisions about continuing or interrupting treatment in high-risk patients should be individualized. Patients at elevated baseline risk who are already using these medications with good results may choose to proceed under closer monitoring, while those who have not yet started treatment may want to explore alternatives or additional screening. This is a conversation best held with both the prescribing physician and, ideally, an ophthalmologist who can assess individual risk factors.
Where Regulatory Agencies and Manufacturers Stand on the Vision Risk
Both major manufacturers have updated their product labeling to include NAION as a rare adverse event. Semaglutide's label now reflects this risk, and tirzepatida's prescribing information was similarly updated. Regulatory agencies worldwide continue to monitor safety data as more information becomes available, and additional label changes or guidance may follow as evidence accumulates.
For detailed regulatory updates and evidence reviews as they are published, TirzeBlog provides accessible summaries without the technical jargon, helping you stay informed without having to dig through agency databases yourself.
What Comes Next: Ongoing Research and What Patients Should Watch
Multiple studies are examining the long-term safety profiles of GLP-1 agonists, including potential cardiovascular and neurological effects. As more real-world data accumulates from the growing population of users, researchers will be better positioned to determine whether a true causal link exists and, if so, which patients are most vulnerable. Historical precedent shows that some early regulatory alerts have been substantiated with time while others have not held up under closer scrutiny.
Healthcare providers play a critical role in this ongoing evaluation. Reporting suspected adverse events, including vision changes in patients using these medications, helps build the evidence base. Patients can also contribute by keeping detailed records of any visual symptoms and communicating them promptly to their doctors.
The TirzeBlog team will continue tracking ANVISA's investigation, FDA updates, and new research as it becomes available. Subscribe to stay informed about what these developments mean for your treatment decisions.
FAQ
Can using weight loss pens cause permanent blindness?
NAION, which has been reported in patients using GLP-1 weight loss medications, can cause permanent vision loss in some cases. However, a causal relationship has not been definitively established, and the overall risk appears to be rare.
Should I stop taking my weight loss medication if I am worried about vision loss?
Do not stop treatment without speaking to your healthcare provider first. Discuss your specific risk factors and any visual symptoms you experience. Abruptly stopping these medications can have other health consequences that need to be considered.
What are the warning signs of NAION that I should watch for?
Sudden vision loss, new blind spots, a gray area in your vision, or color vision changes affecting one or both eyes are signs that require urgent ophthalmologic evaluation.
Are there specific risk factors that make someone more likely to develop NAION while using these medications?
Yes. Pre-existing conditions that affect blood vessels, such as hypertension, diabetes, and sleep apnea, as well as having a structurally crowded optic disc, can increase baseline NAION risk. Patients with these conditions should discuss screening options with their doctor before starting treatment.
Is tirzepatida more likely to cause vision problems than semaglutide?
Current evidence does not show a clear difference between these medications regarding NAION risk. Both are under regulatory review, and the dual mechanism of tirzepatida is being studied to determine whether it presents a distinct risk profile, though no conclusive findings exist at this time.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Never miss a dose and track everything
Injection reminders, a dose history and a side-effects diary — all organized to bring to your appointment.
or download the app
